Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People With and Without Type 1 Diabetes
Authors' conclusion
Persons with and without T1D have similar humoral antibody responses to SARS-CoV-2 mRNA vaccines during 12-months of follow-up.
Study context
- Population
- Adults who received at least two doses of mRNA-1273 or BNT162b2 SARS-CoV-2 vaccine
- Participants
- 27 vs 89
- Exposure
- T1D vs control subjects
- T1Dn = 27
- Controln = 89reference
- Outcome
- Total antibodies against the receptor-binding domain and neutralizing antibodies
- Follow-up
- 12 months
Methodological details12-month follow-up
- 12-month follow-up
Main finding
As reported in the abstract
Antibody levels after vaccination · 12-month follow-up
- Antibody levels did not differ between T1D and non-T1D groups
Observational data: associations, not effects.
Further findings
Breakthrough infection rates
- Breakthrough infection rates did not differ between T1D and non-T1D groups
Determinants of antibody response
- Older age predicted lower antibody levels; SARS-CoV-2 infection or booster gave higher levels in both groups
- mRNA-1273 associated with higher antibody levels than BNT162b2 until 6 months after first dose
- Multivariate repeated measures model
Original publication
Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People With and Without Type 1 Diabetes. Diabetes Technol Ther. Published 12 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →